linjc16/ctgov huggingface dataset:
Ketamine Prevent POCD

Study Overview
=================
Brief Summary
-----------------
Previous study demonstrated that neuroinflammation induced by surgery is the main cause of the postoperative cognitive dysfunction. As an agonist of NMDA receptor, ketamine is proved to be an anti-inflammation agent. In present study investigators hypothesized that low dose ketamine would prevent the cognition decline after orthopedic surgery in aged patients.

Official Title
-----------------
Low Dose Ketamine Prevent the Postoperative Cognitive Dysfunction in Aged Patients Underwent Orthopaedic Surgery，a Randomized Control Double Blinded Multicenter Clinical Trail

Conditions
-----------------
Necrosis of Femoral Head, Knee Osteoarthritis

Intervention / Treatment
-----------------
* Drug: Ketamine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elder than 60 Easily communicated with Chinese Selected to kneel or hip replacement Agree to take part into this clinical trail Exclusion Criteria: Existing cerebral disease， or have a history of neurological and psychiatric disease including AD, stroke and psychosis Existing cognitive impairment as evidenced by Mini-Mental State Examination scores below 24 Several audition or vision disorder Preoperative systolic Blood pressure over 190mmHg or diastolic pressure >100mmHg Existing a history of hyperthyroidism Patient with glaucoma Unwillingness to comply with the protocol or procedures

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ketamine<br>Ketamine infusion group | Drug: Ketamine<br> <br> |
| Placebo Comparator: Placebo<br>Normal saline infusion | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Short-term cognitive changes after surgery | Investigators would use mini-mental state examination(MMSE), Visual reproduction test,digit symbol，digit span,color trail test and Stroop color and word test for measuring the short-term cognitive changes of patients after surgery. | The day before surgery and 7 days after surgery (or before leave hospital) | 
| Long-term cognitive changes after surgery | Investigators would use mini-mental state examination(MMSE), Visual reproduction test,digit symbol，digit span,color trail test and Stroop color and word test for measuring the long-term cognitive changes of patients after surgery. | The day before surgery and 2 months after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Postoperative cognitive dysfunction, Ketamine, Surgery
Surgical Management of Placenta Accreta

Study Overview
=================
Brief Summary
-----------------
purpose of this study was to report our experience for surgical management of suspected placenta accreta cases encountered in King Hussein medical center

Detailed Description
-----------------
was a retrospective study of all patients who underwent planned deliveries for placenta accreta at King Hussein Medical Centre (KHMC) from August 2011 to October 2014.Demographic characteristics were recorded. Ultrasound (U/S) and magnetic resonance imaging (MRI) were used for the diagnosis. Surgery for all patients were performed by multidisciplinary teams. All information were obtained from patient's files.

Official Title
-----------------
Surgical Management of Placenta Accreta a Three Year Experience at King Hussein Medical Center

Conditions
-----------------
To Publish Our Experience in the Surgical Management to Placenta Accreta Cases and the Maternal Outcome

Intervention / Treatment
-----------------
* Procedure: Bakrey balloon insertion within the uterus and caesarean hysterectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all placenta previa accreta cases encountered in our institution over three year period Exclusion Criteria: -
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Bakrey balloon insertion within the uterus and caesarean hysterectomy|Creating an intrauterine tamponade to stop the uterine bleeding by inflating an intrauterine balloon with 600 cc of saline versus undergoing hysterectomy if conservative management failed|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The intraoperative and short term postoperative complications of surgical interventions in placenta accreta | Intraoperative visceral injuries, bleeding, and short term postoperative morbidity and mortality | 48 hours |
Lactate Imaging as a Tumour Biomarker

Study Overview
=================
Brief Summary
-----------------
This project is designed to investigate whether measurements of lactate in tumours, made using a magnetic resonance technique similar to MRI, is an effective non-invasive method to detect whether some new targeted drugs are having their desired effect. The study hypothesis is that by using magnetic resonance spectroscopy techniques, we will be able to observe changes in tumour lactate levels in vivo, in response to treatment.

Official Title
-----------------
Investigation of Lactate Measured Using Magnetic Resonance Spectroscopy as a Biomarker of Tumour Response

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Device: Magnetic Resonance Imaging (MRI)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cohort 1:lymphoma patients minimum lesion size of 2cm not pretreated but scheduled to be treated with CHOP (Cyclophosphamide, Hydroxydaunomycin,Oncovin and Prednisolone) Cohort 2:Colorectal patients metastatic disease of at least 2cm not pretreated Cohort 3:Phase 1 Drug Development minimum lesion size at least 2cm Cohort 4: Brain primary brain tumours receiving radiotherapy and temozolomide cerebral lymphoma receiving standard chemotherapy Exclusion Criteria: MRI incompatible metal implants Claustrophobia Inability to tolerate a 40 minute MRI scan

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lymphoma<br>Lymphoma patients before and after receiving standard CHOP therapy | Device: Magnetic Resonance Imaging (MRI)<br>* Magnetic Resonance Spectroscopy<br>|
| Metastatic Colorectal<br>Patients with metastatic colorectal cancer | Device: Magnetic Resonance Imaging (MRI)<br>* Magnetic Resonance Spectroscopy<br>|
| Phase 1<br>Patients enrolled in Phase 1 clinical trials of new agents, whose mechanism of action is expected to lead to changes in lactate concentration | Device: Magnetic Resonance Imaging (MRI)<br>* Magnetic Resonance Spectroscopy<br>|
| Brain<br>Patients with primary brain tumours and patients with cerebral lymphoma | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between changes in MRS lactate measurements at two time points after treatment and clinical response |  | 7 and 21 days post treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reproducibility of MRS lactate measurement |  | Two baseline measurements taken at day -7 to 0 pre-treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Magnetic Resonance Spectroscopy, Lactate
Nutritional Intervention for Geriatric Hip Fracture Patients

Study Overview
=================
Brief Summary
-----------------
This is a randomized controlled, observer blinded trial to study the beneficial effect of nutritional supplementation in elderly Hong Kong patients after hip fracture surgery during rehabilitation and at 4 weeks follow up. The control group will receive Calcium and Vitamin D supplementation whereas the intervention group will receive a moderately high dose protein nutritional supplementation in addition to Vitamin D and Calcium. Both groups undergo the same rehabilitation program and dietary counseling before discharge. They are followed up 4 weeks after discharge or completion of supplementation. The outcome parameters are nutritional parameters and rehabilitation outcomes.

Official Title
-----------------
A Randomized Controlled Study of Nutritional Intervention for Geriatric Hip Fracture Patients and Its Effect on Rehabilitation Outcomes

Conditions
-----------------
Hip Fractures

Intervention / Treatment
-----------------
* Dietary Supplement: Protein supplementation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 60 years or older Recent low impact osteoporotic fracture of the proximal femur surgically repaired within 4 weeks before recruitment Exclusion Criteria: Patients who require tube feeding Patients in unstable medical condition Body mass index (BMI) ≧ 25 Malignancy Conditions with contraindication for high protein diet Mentally incapacitated and inability to communicate or understand the consent.

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br> | |
| Experimental: Nutritional Supplementation<br> | Dietary Supplement: Protein supplementation<br>* Ready made protein supplement drinks with approximate protein content of 18-24g per 500ml per day. Caloric content is 490 to 530Kcal depending on the brand of drink.<br>* Other names: Glucerna (Abbott);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nutritional parameters | Biochemical and anthropometric measurements | Change from Baseline in nutritional parameters at discharge from hospital and at 4 weeks after discharge | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rehabilitation Outcomes | functional, strength and mobility measurements | Change from Baseline in rehabilitation outcomes at discharge from hospital and at 4 weeks after discharge | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nutritional support, Rehabilitation outcomes
Smoking Reduction or Cessation With Nicotine Replacement Therapy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the success rate of smoking reduction or cessation with different nicotine products.

Detailed Description
-----------------
To test if smoking reduction or cessation is induced with different nicotine products and to investigate the possible health benefits of smoking reduction

Official Title
-----------------
Smoking Reduction or Cessation With Nicotine Replacement Therapy. A Placebo Controlled Double Blind Trial With Nicotine Gum or Inhaler.

Conditions
-----------------
Smoking Cessation

Intervention / Treatment
-----------------
* Drug: Nicotine gum
* Drug: Placebo gum
* Drug: Nicotine inhaler
* Drug: Placebo inhaler


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age above 18 Smoking >/= 15 cigarettes/day Having smoked for 3 years or more CO >/= 10ppm at inclusion Want to reduce smoking Prepared to adhere to the protocol Willing to provide signed informed consent Having made at least one serious attempt to quit smoking Exclusion Criteria: Unstable angina pectoris, myocardial infarction within the last three months Use of other nicotine-containing products such as cigars, pipes, snuff Current use of NRT or involved in behavioral or pharmacological smoking cessation/reduction program Pregnancy/lactation or intended pregnancy Under psychiatric care or medication that might interfere with the trial Abuse of alcohol or any other drug

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nicotine gum<br>Nicotine gum | Drug: Nicotine gum<br>* 8-12 pieces per day, maximum 24 daily<br>* Other names: Nicorette® Gum;|
| Placebo Comparator: Placebo gum<br>Placebo gum | Drug: Placebo gum<br>* 8-12 pieces per day, maximum 24 daily<br>|
| Active Comparator: Nicotine inhaler<br>Nicotine inhaler | Drug: Nicotine inhaler<br>* 6-12 cartridges per day, maximum 12 daily<br>* Other names: Nicorette® Inhaler;|
| Placebo Comparator: Placebo inhaler<br>Placebo inhaler | Drug: Placebo inhaler<br>* 6-12 cartridges per day, maximum 12 daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in number of smoked cigarettes/day verified by carbon monoxide (CO) levels |  | Baseline to 6 weeks, 3 and 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in laboratory values of cardiovascular risk factors |  | Baseline up to 12 months | 
| Changes in clinical and laboratory exposure parameters |  | Baseline up to 12 months |
A Prospective Randomized Study on Vanguard Cruciate Retaining Versus Vanguard High Flex Posterior Stabilized Total Knee System in the Early Range of Motion

Study Overview
=================
Brief Summary
-----------------
Main Objectives are: Test Difference in terms of early ROM between Vanguard FB CR and Vanguard FB PS. Knees; Demonstrate the comparable ROM of high flex PS to CR.

Official Title
-----------------
A Prospective Randomized Study on Vanguard Cruciate Retaining Versus Vanguard High Flex Posterior Stabilized Total Knee System in the Early Range of Motion

Conditions
-----------------
Total Knee Arthroplasty

Intervention / Treatment
-----------------
* Device: Vanguard PS Knee
* Device: Vanguard CR Knee


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients need total knee replacement
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Vanguard PS Knee | Device: Vanguard PS Knee<br>* Vanguard PS Knee<br>|
| Active Comparator: 2<br>Vanguard CR Knee | Device: Vanguard CR Knee<br>* Vanguard CR Knee<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knee Society Score |  | 6weeks, 6months, 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| WOMAC |  | 6weeks, 6months, 1 year | 
| Oxford Knee |  | 6weeks, 6months, 1 year | 
| Complication |  | Anytime |
Brain Imaging To Examine The Effect Of Naproxen In Hand Osteoarthritis Patients

Study Overview
=================
Brief Summary
-----------------
The study hypothesis is that the relief of pain in patients with osteoarthritis in the hand can be detected by a form of brain scanning that detects which parts of the brain are activated when pain is felt.

Official Title
-----------------
A Study To Determine The Ability Of FMRI To Detect And Quantify The Effect Of Naproxen On Osteoarthritis Of The Hand

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Drug: Naproxen
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Right-handed, post-menopausal female, any race, 50-80 years Clinical diagnosis of osteoarthritis of the hand Estimated pain in this joint of at least 5 on a scale of 0 to 10 Exclusion Criteria: Any patient who smokes more than 5 cigarettes per day Patients receiving some anti-depressant drugs unless the dose is stable Patients unable to be admitted or lie still in an MRI scanner

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: Naproxen<br>* 500 mg BID 7 days<br>|
| Placebo Comparator: Arm 2<br> | Drug: Placebo<br>* BID 7 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in voxel-wise Blood Oxygen Level Dependent (BOLD) signal throughout the brain and changes in pre-defined brain regions of interest. |  | 22 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Whole brain resting-state distribution of Cerebral Blood Flow |  | 22 days | 
| Psychometric measures of pain, namely Daily Pain Diaries and Present Pain Intensity |  | 22 days | 
| Pain induced by a grip task measured with a Visual Analogue Scale (VAS), the Short-Form McGill Pain Questionnaire and patient-rated wrist/hand evaluation (PRWHE) |  | 22 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fMRI functional magnetic resonance imaging Pain
Does Preoperative Administration of Oral Doxycycline Decrease the Colonization Rate of Propionibacterium Acnes in the Dermis of the Shoulder?

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the ability of oral doxycycline to decrease the colonization of Propionibacterium acnes in the dermis of the shoulder.

Official Title
-----------------
Does Preoperative Administration of Oral Doxycycline Decrease the Colonization Rate of Propionibacterium Acnes in the Dermis of the Shoulder?

Conditions
-----------------
Propionibacterium

Intervention / Treatment
-----------------
* Drug: Doxycycline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -All male patients (>18 years of age) undergoing shoulder arthroscopy Exclusion Criteria: Female patients patients with active acne patients who have taken antibiotics in the past month doxycycline allergy benzoyl peroxide allergy clindamycin allergy patients with psoriatic/eczematous or other lesions on the shoulder girdle.

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Parallel Assignment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>Standard of care | |
| Active Comparator: Treatment<br>Oral doxycycline | Drug: Doxycycline<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantification of P acnes grown from anaerobic or aerobic culture |  | within 14 days of surgery |
Analysis of Related Factors Affecting the Secondary Implantation of Intraocular Lens in Congenital Cataract

Study Overview
=================
Brief Summary
-----------------
The ocular biometric parameters of the children with congenital cataract including preoperative pupil diameter, corneal diameter, axial length, anterior and posterior capsule size, iris adhesion. And then analysis whether the preoperative parameters were correlated with the implantation site of secondary implantation.

Official Title
-----------------
Analysis of Related Factors Affecting the Secondary Implantation of IOLs in Congenital Cataract

Conditions
-----------------
Congenital Cataract

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients were diagnosed as congenital cataract without lens after surgery Secondare IOLs implantation surgery was performed in Eye hospital of Wenzhou Medical University Exclusion Criteria: Suffers from uveitis, glaucoma and other ocular diseases
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pupil diameter | preoperative pupil diameter size | Before lens implantation | 
| posterior capsule diameter | preoperative posterior capsule diameter size | Before lens implantation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
secondary implantation, ciliary sulcus